CN2817764Y - Transcutaneous active pulse valvular displacing device - Google Patents
Transcutaneous active pulse valvular displacing device Download PDFInfo
- Publication number
- CN2817764Y CN2817764Y CN 200620068479 CN200620068479U CN2817764Y CN 2817764 Y CN2817764 Y CN 2817764Y CN 200620068479 CN200620068479 CN 200620068479 CN 200620068479 U CN200620068479 U CN 200620068479U CN 2817764 Y CN2817764 Y CN 2817764Y
- Authority
- CN
- China
- Prior art keywords
- valve
- aortic
- support
- aortic valve
- sanye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Prostheses (AREA)
Abstract
The utility model designs a novel transcutaneous aortic valve replacing device which has the advantages of reasonable structure, easy use and low operation risk, and aims at the problems that the existing transcutaneous aortic valve replacing device has inconvenience of suturing a valve and a stent, which causes difficulty in complete suture; an aortic valve is dilated beforehand by a balloon during an operation, which has a high operation risk. The utility model is a self-expanding stent with a biological valve, and is composed of a trefoil unidirectional open valve, etc. which is composed of the stent and a pig pericardium of a special shape of a nitinol alloy skeleton, wherein the nitinol alloy stent has the functions of fixation and support, and the pig pericardium are sutured into three valves which are firmly fixed in the stent. The novel transcutaneous aortic valve replacing device has the advantages of small trauma and high safety, and reduces the complications of aortic valve replacement.
Description
Technical field
This utility model relates to a kind of medical apparatus and instruments, and need not operating on that especially a kind of division of cardiology uses can be carried out the prosthetic aortic valve that aortic valve is replaced, specifically a kind of percutaneous aortic valve replacement device.
Background technology
From nineteen sixty Starr and Harken respectively the using artificial valve replaced for patient since Bicuspid valve and aortic valve succeed, the surgery valve replacement surgery is as the most effectual way of serious valvular heart disease treatment, and be that the above patient of 100,000 examples carries out valve replacement surgery every year.The artificial valve is divided into bioprosthetic valve and mechanical prosthetic valve two big classes, kind more than 100, clinical use respectively has pluses and minuses, and most artificial valve replacement operation all carries out under the support of body pulmonary circulation machine, and the complicated first heart of infant and the old valve patient's of serious symptom artificial valve replacement operation is restricted.Over nearly 5 years, constantly there is new artificial valve to emerge in large numbers, make artificial valve's replacement operation begin need not the support of body pulmonary circulation, particularly through the successful Application of conduit prosthetic valve replacement, for the treatment of valvular heart disease has increased new tool at animal and special case.
Age surpasses among 65 years old old people, because the aortic stenosis incidence rate due to the aortic valve calcification reaches 2%～7%, and ratio is more and more higher with age.Serious aortic stenosis patient left heart function is badly damaged, and patient descends quality of life and life span obviously shortens, and must effectively treat.Up to now, the serious aortic valve patient of surgical operation indication is arranged, surgery aortic valve prosthesis replacement (no matter selecting mechanical prosthetic valve or bioprosthetic valve for use) remains first-selected treatment.Percutaneous sacculus aortic valve plasty, because in the art, the severe postoperative complication comprises: death, apoplexy, aortic rupture, the serious incompetence of aortic valve and aortic valve restenosis incidence rate height in a short time, not as the serious Therapeutic Method of aortic stenosis.The elderly patients of serious aortic stenosis or incompetence, during no surgical operation indication, clinical treatment is very difficult.Become the another selection of above-mentioned patient through conduit aortic valve prosthesis replacement.
2002, Philipp Bonhoeffer reported the animal test results through conduit aortic valve prosthesis replacement.He utilizes diameter to tear the sheep aortic valve for 10mm or 18mm balloon expandable, produces moderate and severe aortic incompetence.Stent valve is made up of three parts: 1. outer self-inflated nick-eltitanium alloy stent: weave into diameter 25mm blank pipe shape structure by nitinol alloy wire, on nearly aorta limit 3 equally distributed projections are arranged, play fixedly aortic valve; 2. internal layer balloon expandable platinumiridio support and 3. bioprosthetic valve.Outer support and internal layer support are all sewed up except that projection and are close to.Band lobe bovine jugular vein is cut off corresponding breach in the venous valve upper part, and avoiding stent valve to insert the back influences coronary flow.
2002, Alain Cribier is carrying out on a large amount of zooperal bases, be that 57 years old serious aortic stenosis patient of 1 example has carried out the replacement through the conduit aortic valve prosthesis first, to 2004, be again that 8 examples are that the patient of the severe aortic stenosis of 82.6 years old (77～88 years old) has carried out valve replacement surgery the mean aves.EDWARDS company in 2004 suspended a drugs approved by FDA through conduit aortic valve prosthesis replacement operation because direct motion method complication rate in art of previous application was higher than retrograde method, require to increase the method for driving in the wrong direction displacement aortic valve.
In sum, existing percutaneous aortic valve replacement device has the following disadvantages: the calcification problem of biovalve is not resolved; The stitching of valve and support is complete inadequately in the valve system; Induction system is required high; Need expand aortic valve in advance with sacculus, there are a series of problems such as the complex structure manufacture difficulty is big in addition in the operation risk height.
Summary of the invention
To such an extent as to the purpose of this utility model be the valve that exists at existing percutaneous aortic valve replacement device with support sew up inconvenience be difficult to sew up fully and perform the operation in need expand aortic valve in advance with sacculus and have the high problem of operation risk, design a kind of rational in infrastructure, easy to use, the novel percutaneous aortic valve replacement device that operation risk is little.
The technical solution of the utility model is:
A kind of percutaneous aortic valve replacement device, comprise the latticed support 1 that forms by the nitinol alloy wire braiding, SANYE valve 2, SANYE valve 2 is by being fixed in the support 1 with the support 1 circumferential film 3 that links to each other, it is characterized in that described support 1 is by mutual perforation, the aortic stents 6 of Xiang Lianing successively, valve bracket 5, left ventricular outflow tract support 4, one end of aortic stents 6 is for ease of the no bottom structure to the aorta blood supply, its other end links to each other with an end of valve bracket 5, the other end of valve bracket 5 links to each other with an end of left ventricular outflow tract support 4, the other end of left ventricular outflow tract support 4 is one to be convenient to the no bottom structure that the left ventricular blood liquid stream is gone into, the diameter of the no bottom structure end of described aortic stents 6 is greater than the no bottom structure end of left ventricular outflow tract support 4 and the diameter of valve bracket 5, film 3 is fixed on the inwall of valve bracket 5, and SANYE valve 2 links to each other with film 3 and is positioned in the valve bracket 5.
Described film 3 is a poly tetrafluoroethylene, and it links to each other with valve bracket 5 and SANYE valve 2 respectively by medical suture.
Described SANYE valve 2 is made by the unidirectional open valve of forming through the Cor Sus domestica bag of anti-calcification processing of SANYE and is formed.
The diameter of described aortic stents 6 is greater than by 10%～20% of displacer aorta diameter.
The utlity model has following advantage:
1, need not external cardiorespiratory system just can finish the displacement of aortic valve; The induction system of 14F; The self-expanding function without sacculus, has been avoided the interruption of aortic flow; Blood flow coronarius is guaranteed; The calcification speed of valve reduces, and the life-span prolongs.
2, use aortic valve replacement device of the present utility model under the situation of not opening breast, to adopt transcatheter method that the aortic valve replacement device is implanted to the aortic valve position, reduce operation misery and risk, for patient reduces medical expense.
3, support of the present utility model and valve are linear when being subjected to the external force tractive, and valve system is injury-free behind the shape that resiles, and this characteristics make it easy to operate, are the metathetical prerequisites of percutaneous.
4, nick-eltitanium alloy stent designs according to left ventricular outflow tract, aortal shape, after discharging, device can combine closely with left ventricular outflow tract, aorta, guaranteeing that percutaneous aortic valve replacement device can be stablized is placed on left ventricular outflow tract and aorta, do not damage left ventricular outflow tract and aorta again, the aorta inner support partly plays main fixedly percutaneous aortic valve replacement device, and valve bracket has guaranteed that support does not bounce back and do not have perivalvular leakage.
5, SANYE valve of the present utility model has the function of one-way cock, can guarantee that blood is open at the left ventricle systole, and close at relaxing period, recovers the function of aortic valve.
6, the Cor Sus domestica bag of making the SANYE valve is through anti-calcification processing, and it is after implanting, and calcification is obviously slowed down, and obviously prolong its service life.
7, in aortic stents, do not cover inner membrance, effectively guaranteed blood supply coronarius.
8, this utility model can be put into the induction system use of 14F level, and the self-expanding function is arranged, and can recover the function of external shape after discharging outside transmitting sheath.
Description of drawings
Fig. 1 is a structural representation of the present utility model.
Fig. 2 is the vertical view of this Fig. 1.
The specific embodiment
Following structure drawings and Examples are further described this utility model.
As shown in Figure 1, 2.
A kind of percutaneous aortic valve replacement device, comprise the latticed support 1 that forms by the nitinol alloy wire braiding, SANYE valve 2, SANYE valve 2 is made by the unidirectional open valve of forming through the Cor Sus domestica bag of anti-calcification processing of SANYE and is formed, it is by being fixed in the support 1 with the support 1 circumferential poly tetrafluoroethylene 3 that links to each other, support 1 is by mutual perforation, the aortic stents 6 of Xiang Lianing successively, valve bracket 5, left ventricular outflow tract support 4, one end of aortic stents 6 is for ease of the no bottom structure to the aorta blood supply, its other end links to each other with an end of valve bracket 5, the other end of valve bracket 5 links to each other with an end of left ventricular outflow tract support 4, the other end of left ventricular outflow tract support 4 is one to be convenient to the no bottom structure that the left ventricular blood liquid stream is gone into, the diameter of the no bottom structure end of described aortic stents 6 is greater than the no bottom structure end of left ventricular outflow tract support 4 and the diameter of valve bracket 5, poly tetrafluoroethylene 3 is fixed on the inwall of valve bracket 5, SANYE valve 2 links to each other with poly tetrafluoroethylene 3 and is positioned in the valve bracket 5, and poly tetrafluoroethylene 3 links to each other with valve bracket 5 and SANYE valve 2 respectively by medical suture.
Percutaneous aortic valve replacement device of the present utility model has good shape memory function, is linear when being subjected to the external force tractive, and external force is recovered original-shape after removing immediately.
Cor Sus domestica bag SANYE valve 2 in this utility model, before stitching, pass through anti-calcification processing, calcification speed obviously descends in its body, prolong physiological longevity, SANYE valve 2 is sewed up with poly tetrafluoroethylene 3, and then poly tetrafluoroethylene 3 sewed up mutually with valve bracket 5, SANYE valve 2 can be firmly and support combine closely.
When this utility model used, whole intervention procedure carried out under the guiding of transesophageal echocardiography, and radiography is estimated the size and the aorta diameter of left ventricular outflow tract, aortic valvular ring, selected people's percutaneous aortic valve replacement device of suitable size.After cutting femoral artery,, it is expanded, reach the purpose of displacement aortic valve in the release of the position of aortic valve along special induction system shipper percutaneous aortic valve replacement device.The aortic root radiography, evaluation has or not aortic regurgitation.
In zoopery and clinical practice, can select the size of percutaneous aortic valve replacement device according to ventriculography of left ventricle in transesophageal echocardiography inspection and the art.Usually selection percutaneous aortic valve replacement device diameter should be bigger by 10%～20% than aorta diameter.Reach once more the radiography result according to the esophagus ultrasound kinetocardiogram and determine percutaneous aortic valve replacement device implantation position and effect.
Below in conjunction with concrete zoopery this utility model is further described.
Test situation is as follows:
5 male miniature pigs, body weight 23-28kg, average 24.6kg.
Whole intervention procedure carries out under X line perspective, under the guiding of transesophageal echocardiography.The laboratory animal dorsal position is fixed in catheter bed.Patients Under Ketamine Anesthesia connects respirator, electrocardiograph after the tracheal intubation.The right femoral artery puncture, import the 14F arterial sheath, left lateral position 90 degree ventriculography of left ventricle, understand left ventricular outflow tract and aortal internal diameter, selection is than the percutaneous aortic valve replacement device of the big 10%-20% diameter of Ad, send into percutaneous aortic valve replacement device through special induction system, discharge percutaneous aortic valve replacement device in the position of aortic valve and make its self-expanding.The aortic root radiography is estimated anti-stream and the blood flow coronarius have or not aortic valve, confirms not have the anti-stream of aortic valve and coronary flow surgeon's knot bundle just often.
Experimental result: 5 animals, except that 1 because of the too much death of intraoperative hemorrhage, all the other 4 survive.Put to death 1 respectively in 2 weeks of postoperative, 4 weeks, 8 weeks, the execution echocardiography that moves ahead, the aortic valve blood flow is normal, the anti-stream that does not have aortic valve is put to death the back gross examination of skeletal muscle, and all the percutaneous aortic valve replacement device position is good, do not see displacement, perusal percutaneous aortic valve replacement device surface and around do not have thrombosis, percutaneous aortic valve replacement device surface about 80% is covered by endothelium during 4 weeks, the percutaneous aortic valve replacement device surface is almost completely covered by endothelium during 8 weeks.
Claims (4)
1, a kind of percutaneous aortic valve replacement device, comprise the latticed support (1) that forms by the nitinol alloy wire braiding, SANYE valve (2), SANYE valve (2) is by being fixed in the support (1) with film (3) that support (1) circumferentially links to each other, it is characterized in that described support (1) is by mutual perforation, the aortic stents of Xiang Lianing (6) successively, valve bracket (5), left ventricular outflow tract support (4), one end of aortic stents (6) is for ease of the no bottom structure to the aorta blood supply, its other end links to each other with an end of valve bracket (5), the other end of valve bracket (5) links to each other with an end of left ventricular outflow tract support (4), the other end of left ventricular outflow tract support (4) is one to be convenient to the no bottom structure that the left ventricular blood liquid stream is gone into, the diameter of the no bottom structure end of described aortic stents (6) is greater than the no bottom structure end of left ventricular outflow tract support (4) and the diameter of valve bracket (5), film (3) is fixed on the inwall of valve bracket (5), and SANYE valve (2) links to each other with film (3) and is positioned in the valve bracket (5).
2, percutaneous aortic valve replacement device according to claim 1 is characterized in that described film (3) is a poly tetrafluoroethylene, and it links to each other with valve bracket (5) and SANYE valve (2) respectively by medical suture.
3, percutaneous aortic valve replacement device according to claim 1 is characterized in that described SANYE valve (2) is made by the unidirectional open valve of forming through the Cor Sus domestica bag of anti-calcification processing of SANYE to form.
4, percutaneous aortic valve replacement device according to claim 1, the diameter that it is characterized in that described aortic stents (6) is greater than by 10%～20% of displacer aorta diameter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200620068479 CN2817764Y (en) | 2006-01-16 | 2006-01-16 | Transcutaneous active pulse valvular displacing device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200620068479 CN2817764Y (en) | 2006-01-16 | 2006-01-16 | Transcutaneous active pulse valvular displacing device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN2817764Y true CN2817764Y (en) | 2006-09-20 |
Family
ID=37003816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200620068479 Expired - Fee Related CN2817764Y (en) | 2006-01-16 | 2006-01-16 | Transcutaneous active pulse valvular displacing device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN2817764Y (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011298B (en) * | 2006-01-16 | 2010-05-26 | 孔祥清 | Device for replacing aortic valve membrane or pulmonary valve membrane percutaneously |
| CN102551919A (en) * | 2011-12-22 | 2012-07-11 | 山东大学 | Artificial cardiac valve and performance analysis method based on ANSYS/LS-DYNA thereof |
| EP2489331B1 (en) | 2010-11-05 | 2017-06-28 | Cook Medical Technologies LLC | Stent structures for use with valve replacement |
| CN109966024A (en) * | 2019-04-26 | 2019-07-05 | 中国人民解放军第四军医大学 | A kind of heart arter valve backflows tester |
| CN115300177A (en) * | 2021-09-16 | 2022-11-08 | 武汉创而研之科技发展有限公司 | Novel intraoperative stent with degradable single valve leaflet |
-
2006
- 2006-01-16 CN CN 200620068479 patent/CN2817764Y/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011298B (en) * | 2006-01-16 | 2010-05-26 | 孔祥清 | Device for replacing aortic valve membrane or pulmonary valve membrane percutaneously |
| EP2489331B1 (en) | 2010-11-05 | 2017-06-28 | Cook Medical Technologies LLC | Stent structures for use with valve replacement |
| US10695171B2 (en) | 2010-11-05 | 2020-06-30 | Cook Medical Technologies Llc | Stent structures for use with valve replacements |
| US11554011B2 (en) | 2010-11-05 | 2023-01-17 | Cook Medical Technologies Llc | Stent structures for use with valve replacements |
| US11602428B2 (en) | 2010-11-05 | 2023-03-14 | Cook Medical Technologies Llc | Stent structures for use with valve replacements |
| US11911270B2 (en) | 2010-11-05 | 2024-02-27 | Cook Medical Technologies Llc | Stent structures for use with valve replacements |
| CN102551919A (en) * | 2011-12-22 | 2012-07-11 | 山东大学 | Artificial cardiac valve and performance analysis method based on ANSYS/LS-DYNA thereof |
| CN102551919B (en) * | 2011-12-22 | 2015-04-08 | 山东大学 | Artificial cardiac valve and performance analysis method based on ANSYS/LS-DYNA thereof |
| CN109966024A (en) * | 2019-04-26 | 2019-07-05 | 中国人民解放军第四军医大学 | A kind of heart arter valve backflows tester |
| CN109966024B (en) * | 2019-04-26 | 2024-02-06 | 中国人民解放军第四军医大学 | Heart valve reflux tester |
| CN115300177A (en) * | 2021-09-16 | 2022-11-08 | 武汉创而研之科技发展有限公司 | Novel intraoperative stent with degradable single valve leaflet |
| CN115300177B (en) * | 2021-09-16 | 2024-06-11 | 武汉创而研之科技发展有限公司 | Novel intraoperative support with degradable single valve leaflet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011298B (en) | Device for replacing aortic valve membrane or pulmonary valve membrane percutaneously | |
| CN1799520A (en) | Percutaneous aortic valve replacement device | |
| US20240164892A1 (en) | Retrievable Transcatheter Cardiovascular Prosthetic Aortic Heart Valve | |
| JP6006218B2 (en) | Aortic valve device | |
| CA2333409C (en) | Separable annuloplasty ring | |
| US20170325943A1 (en) | Profile reduction of valve implant | |
| AU2008288796B2 (en) | Cardiovascular prosthetic valve | |
| CN107405194A (en) | Mitral | |
| CN107233146A (en) | It is applicable heart bicuspid valve and tricuspid valve band valve support replacement valve | |
| US20080208329A1 (en) | Handle mechanism to adjust a medical device | |
| JP2009509604A (en) | Ascending aortic segment prosthesis and surgical treatment of aortic valve leak | |
| CN2817764Y (en) | Transcutaneous active pulse valvular displacing device | |
| CN109907860A (en) | Artificial Valved allograft | |
| EP4046602A1 (en) | Self-extendable stent for pulmonary artery | |
| RU2734748C2 (en) | Method for prosthetic repair of all structures of aortic root | |
| Bronzino et al. | Soft Tissue Replacements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060920 Termination date: 20150116 |
|
| EXPY | Termination of patent right or utility model |